News | May 08, 2026
Sanofi India partners with NHM MP to expand NCD, rare disease services
The partnership will focus on diabetes and NCD awareness, rare disease screening, and deployment of mobile medical units
The partnership will focus on diabetes and NCD awareness, rare disease screening, and deployment of mobile medical units
Approval strengthens the company’s growing international anti-infective portfolio
Supported by Plan International, the partnership will help treat over 1,000 children annually
Complex tumour removed in a young patient without major pancreatic loss, reducing risk of lifelong diabetes
The initiative by DKMS Foundation India is for below 12 years children suffering from transfusion-dependent thalassemia
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The standout story remains Wegovy, particularly its new oral formulation
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
